Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18434731 | DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF | February 2024 | December 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18385771 | TREATMENT OF HPV INFECTION | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18069541 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | December 2022 | May 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 17934896 | Methods of Suppression and Treatment of Disease Comprising administering Bicycle Peptide Ligands Specific for EphA2 | September 2022 | July 2023 | Allow | 10 | 0 | 0 | Yes | No |
| 17822161 | ANTIMICROBIAL PEPTIDES AND RELATED METHODS | August 2022 | February 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 17816954 | ANTICANCER PEPTIDE AND USE THEREOF FOR INHIBITING CANCER CELL VIABILITY | August 2022 | October 2023 | Abandon | 15 | 1 | 0 | Yes | No |
| 17864702 | Methods of Treating Alzheimer's Disease | July 2022 | November 2024 | Abandon | 28 | 3 | 0 | No | No |
| 17810404 | MNK INHIBITORS AND EIF4E PHOSPHORYLATION MODULATION TO TREAT INFLAMMATORY PAIN IN THE AGED | July 2022 | August 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17846227 | Method of Preparing Crosslinked Hydrogels, Resulting Muscle Stem Cell Culture Media, and Methods of Use. | June 2022 | February 2023 | Allow | 8 | 1 | 1 | No | No |
| 17731312 | ATOPIC DERMATITIS THERAPY WITH KAPPA OPIOID RECEPTOR AGONIST AS ADJUNCT TO TOPICAL CORTICOSTEROID | April 2022 | January 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17727276 | ICD PEPTIDE AND USE THEREOF FOR HAVING CYTOTOXIC ACTIVITY ON CANCER CELLS | April 2022 | November 2023 | Abandon | 18 | 1 | 1 | No | No |
| 17722081 | COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITY | April 2022 | May 2023 | Allow | 13 | 0 | 1 | Yes | No |
| 17707332 | INHIBITION OF TUMOR NECROSIS FACTOR, PRO-INFLAMMATORY CYTOKINES AND OTHER IMFLAMMATORY RESPONSE MEDIATORS | March 2022 | April 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17680271 | BVP10 PROTEIN FOR CONTROLLING TETRANYCHID MITES AND USE THEREOF | February 2022 | September 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17678403 | METHOD OF ADMINISTERING A DUAL THERAPEUTIC AND COSMETIC AGENT | February 2022 | May 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17456628 | FORMULATIONS FOR TREATING CRAMPS AND SPASMS | November 2021 | November 2024 | Allow | 35 | 2 | 0 | No | No |
| 17602750 | APPETITE SUPPRESSION WITH PHARMACEUTICAL COMPOSITIONS CONTAINING BIGLYCAN AS AN ACTIVE INGREDIENT | October 2021 | March 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17409433 | 3D PHARMACOPHORE MODEL FOR THE RAPID COMPUTATIONAL SCREENING OF SARS-COV-2 MODULATORS AND COMPOSITIONS AND METHODS THEREOF | August 2021 | August 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17388846 | METHOD OF PROGNOSIS OF BRONCHOPULMONARY DYSPLASIA IN PREMATURE INFANTS | July 2021 | January 2025 | Abandon | 41 | 2 | 1 | Yes | No |
| 17311789 | AN IMPROVED PROCESS FOR THE PREPARATION OF PLECANATIDE | June 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17295360 | LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF | May 2021 | April 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17288197 | ANTI-OBESITY AGENT, POLLAKIURIA IMPROVING AGENT, AND AUTONOMIC NERVOUS ACTIVITY REGULATOR | April 2021 | August 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17284343 | PEPTIDE FOR COSMETIC APPLICATION | April 2021 | May 2024 | Abandon | 37 | 3 | 0 | Yes | No |
| 17223629 | NOVEL ARID5A PEPTIDE INHIBITORS | April 2021 | August 2023 | Allow | 28 | 2 | 0 | No | No |
| 17215089 | METHOD OF TREATING VIRAL INFECTIONS | March 2021 | February 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17278532 | ANTI-MICROBIAL PEPTIDES | March 2021 | August 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17277783 | METHODS OF PHYSICOCHEMICAL-GUIDED PEPTIDE DESIGN AND NOVEL PEPTIDES DERIVED THEREFROM | March 2021 | June 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17203126 | LIQUID FORMULATIONS OF GLUCAGON ANALOGUES | March 2021 | January 2025 | Abandon | 46 | 3 | 0 | No | Yes |
| 17200204 | COMPOSITIONS AND METHODS RELATING TO INHIBITORS OF PRO-INFLAMMATORY CYTOKINES AND CHEMOKINES FOR TREATMENT OF CANCER | March 2021 | February 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17274666 | DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF | March 2021 | December 2024 | Allow | 46 | 2 | 1 | No | No |
| 17274721 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | March 2021 | October 2023 | Allow | 31 | 3 | 1 | Yes | No |
| 17193832 | TREATMENTS FOR IMPROVING OR LESSENING IMPAIRMENT OF MITOCHONDRIAL FUNCTION | March 2021 | October 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17272010 | NOVEL USE OF PEPTIDE FOR INHIBITING FUNCTIONS AND EXPRESSIONS OF MULTIPLE DISEASE BIOMARKERS | February 2021 | March 2024 | Abandon | 36 | 3 | 1 | No | No |
| 17184433 | USE OF CYCLOSPORINE ANALOGUES FOR TREATING CANCER | February 2021 | June 2024 | Abandon | 40 | 4 | 1 | No | No |
| 17249119 | PEPTIDES FOR TREATING MUCOSA | February 2021 | October 2022 | Abandon | 20 | 1 | 1 | Yes | No |
| 17268818 | STAPLED H2 PYRIN PEPTIDES | February 2021 | April 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17267876 | Self-Assembling Multi-Domain Peptide Based Hydrogels | February 2021 | January 2025 | Abandon | 47 | 4 | 1 | Yes | No |
| 17170790 | ORAL PEPTIDE ANTAGONISTS OF MULTIPLE CHEMOKINE RECEPTORS FOR REVERSING LOSS OF SYNAPSES AND DENDRITIC SPINES | February 2021 | February 2024 | Abandon | 36 | 3 | 0 | Yes | No |
| 17161528 | METHOD OF OPERATING REDUNDANT STAGGERED DISEASE MANAGEMENT SYSTEMS | January 2021 | May 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17157592 | PHARMACEUTICAL COMPOSITION AND A METHOD FOR ITS MANUFACTURE | January 2021 | March 2023 | Abandon | 26 | 2 | 0 | Yes | No |
| 17261249 | PEPTIDE FOR REGULATING REACTIVITY TO SEROTONIN REUPTAKE INHIBITOR BASED ANTIDEPRESSANT, AND USE THEREOF | January 2021 | December 2021 | Allow | 10 | 0 | 0 | Yes | No |
| 17260934 | Isolated darobactin A analog compounds and compositions thereof. | January 2021 | September 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 17258170 | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF | January 2021 | June 2024 | Allow | 42 | 4 | 1 | Yes | Yes |
| 17142051 | CELL PENETRATING SHORT PEPTIDE TAT-HUR-HNS-3 AND APPLICATION THEREOF IN INFLAMMATORY DISEASE | January 2021 | September 2022 | Abandon | 21 | 1 | 1 | Yes | No |
| 17254234 | "�-1,3-GLUCAN-PEPTIDE COMPLEX: COMPOSITIONS AND METHODS | December 2020 | December 2021 | Allow | 12 | 0 | 0 | Yes | No |
| 17253774 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | December 2020 | July 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 17251019 | POLYPEPTIDES, NUCLEIC ACID MOLECULES, COMPOSITIONS, AND RELATED METHODS | December 2020 | March 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17114443 | Peptide Docking Vehicle for Targeted Nucleic Acid Delivery | December 2020 | March 2024 | Allow | 40 | 1 | 2 | Yes | No |
| 17056193 | CARDIAC-SPECIFIC TARGETING-PEPTIDE (CTP), COMPOSITIONS, AND USES THEREOF | November 2020 | August 2023 | Abandon | 33 | 2 | 1 | Yes | No |
| 17053548 | PROCESS FOR PREPARATION OF PURE PLECANATIDE | November 2020 | December 2022 | Abandon | 26 | 1 | 1 | No | No |
| 17053047 | APPLICATION OF PEDF-DERIVED SHORT PEPTIDES IN TENDON HEALING | November 2020 | May 2022 | Abandon | 18 | 1 | 1 | No | No |
| 17045085 | PEPTIDE NANOFIBERS | October 2020 | March 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17040973 | GLUCOSE-RESPONSIVE INSULIN | September 2020 | November 2023 | Abandon | 38 | 0 | 1 | No | No |
| 17015187 | TREATMENT OF A HEART DISEASE | September 2020 | December 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16969062 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | August 2020 | August 2023 | Abandon | 36 | 3 | 1 | Yes | No |
| 16989843 | METHOD FOR BIOCATALYTIC PROTEIN-OLIGONUCLEOTIDE CONJUGATION | August 2020 | April 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 16938758 | PEPTIDES FOR TREATING NON-EXUDATIVE MACULAR DEGENERATION AND OTHER DISORDERS OF THE EYE | July 2020 | April 2024 | Abandon | 45 | 1 | 1 | Yes | No |
| 16964566 | CATIONIC PEPTIDES WITH IMMUNOMODULATORY AND/OR ANTI-BIOFILM ACTIVITIES | July 2020 | June 2024 | Abandon | 47 | 3 | 1 | No | No |
| 16962082 | PEPTIDES AND USES THEREOF | July 2020 | June 2024 | Abandon | 47 | 3 | 1 | No | Yes |
| 16961667 | ANTI-LEUKEMIC, ANTI-HIV, AND SIALIDASE ACTIVITIES OF ROYAL-JELLY PROTEINS | July 2020 | March 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16959533 | COMPOUNDS AND METHODS FOR REDUCING OR INHIBITING AGGREGATION OF PROTEINS IN A SUBJECT | July 2020 | November 2021 | Allow | 17 | 0 | 0 | Yes | No |
| 16772810 | PEPTIDES FOR BINDING TO CD44V6 AND USE THEREOF | June 2020 | October 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16770532 | TREATMENT WITH NMDA RECEPTOR MODULATORS | June 2020 | March 2022 | Abandon | 22 | 0 | 1 | No | No |
| 16767523 | USE OF KOR AGONIST IN COMBINATION WITH MOR AGONIST IN PREPARING DRUG FOR TREATING PAIN | May 2020 | June 2022 | Allow | 25 | 1 | 1 | No | No |
| 16629183 | BIOCONJUGATES WITH CHEMICALLY MODIFIED BACKBONES | January 2020 | September 2023 | Allow | 44 | 3 | 1 | Yes | No |
| 16684082 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | November 2019 | September 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16603352 | COVERSIN (OmCl) FOR THE TREATMENT OF AUTOIMMUNE BLISTERING DISEASES: BULLOUS PEMPHIGOID (BP) AND EPIDERMOLYSIS BULLOSA ACQUISITA (EBA) | October 2019 | May 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16568913 | SYNTHETIC BLOOD VESSELS AND USES THEREOF | September 2019 | March 2022 | Allow | 30 | 0 | 1 | Yes | No |
| 16489302 | NANOSCALE DRUG CARRIER CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | August 2019 | March 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16488180 | PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME | August 2019 | November 2023 | Abandon | 50 | 2 | 1 | Yes | No |
| 16472298 | NEW STAPLED PEPTIDES AND USES THEREOF | June 2019 | February 2022 | Allow | 31 | 0 | 1 | Yes | No |
| 16462922 | CELL-PENETRATING PEPTIDE SEQUENCES | May 2019 | October 2024 | Abandon | 60 | 6 | 1 | Yes | No |
| 16334734 | A METHOD OF DETECTING DISEASED OR DAMAGED TISSUE WITH A PH-TRIGGERED POLYPEPTIDE FLUOROPHORE COMPOSITION. | March 2019 | August 2022 | Allow | 41 | 2 | 1 | Yes | No |
| 16220685 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | December 2018 | June 2022 | Allow | 42 | 1 | 1 | Yes | No |
| 15779237 | OPTIMIZED RATIOS OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS | May 2018 | April 2023 | Abandon | 59 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CRONIN, JOHN MICHAEL.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CRONIN, JOHN MICHAEL works in Art Unit 1658 and has examined 74 patent applications in our dataset. With an allowance rate of 47.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner CRONIN, JOHN MICHAEL's allowance rate of 47.3% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CRONIN, JOHN MICHAEL receive 1.58 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CRONIN, JOHN MICHAEL is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +53.6% benefit to allowance rate for applications examined by CRONIN, JOHN MICHAEL. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.